glp-1 news september 2025 30 Repositioning GLP-1 Drugs for Neurologic Disease: Evidence, Advances, and Outlook Understanding GLP-1s and their dynamic
Description
Specialist supervision is required, and patients should discuss potential risks and interactions with their physician before starting any GLP-1 microdosing protocol
2023, www.uptodate.com/contents/glucagon-like-peptide-1-based-therapies-for-the-treatment-of-type-2-diabetes-mellitus/print?search=tirzepatide&source=search_result&selectedTitle=1~5&usage_type=default&display_rank=1
Ongoing clinical and mechanistic studies are expected to expand use of GLP-1 receptor agonists, glucose-dependent insulinotropic polypeptide agonists and other metabolic hormones for the treatment of chronic kidney disease
This feedback loop can reinforce itself if the underlying metabolic drivers are not addressed
